Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.

Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B

Open source

DOI: 10.1016/s1470-2045(25)00032-4
Published: 2025 Apr
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00032-4,
  title = {Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.},
  author = {Powles T and Choueiri TK and Albiges L and Peltola K and de Velasco G and Burotto M and Suarez C and Ghatalia P and Iacovelli R and Lam ET and Verzoni E and Gümüş M and Stadler WM and Kollmannsberger C and Melichar B and Venugopal B and Gross-Goupil M and Poprach A and De Santis M and Rizzo M and Shinde R and Saretsky TL and He L and Perini RF and Vickery D and Rini B},
  year = {2025},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00032-4},
  url = {https://doi.org/10.1016/s1470-2045(25)00032-4}
}

RIS

TY  - JOUR
TI  - Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
AU  - Powles T
AU  - Choueiri TK
AU  - Albiges L
AU  - Peltola K
AU  - de Velasco G
AU  - Burotto M
AU  - Suarez C
AU  - Ghatalia P
AU  - Iacovelli R
AU  - Lam ET
AU  - Verzoni E
AU  - Gümüş M
AU  - Stadler WM
AU  - Kollmannsberger C
AU  - Melichar B
AU  - Venugopal B
AU  - Gross-Goupil M
AU  - Poprach A
AU  - De Santis M
AU  - Rizzo M
AU  - Shinde R
AU  - Saretsky TL
AU  - He L
AU  - Perini RF
AU  - Vickery D
AU  - Rini B
PY  - 2025
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00032-4
UR  - https://doi.org/10.1016/s1470-2045(25)00032-4
ER  -

APA

T, P., TK, C., L, A., K, P., G, D. V., M, B., C, S., P, G., R, I., ET, L., E, V., M, G., WM, S., C, K., B, M., B, V., M, G., A, P., M, D. S., M, R., R, S., TL, S., L, H., RF, P., D, V., & B, R. (2025). Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00032-4

Source records

pubmed · retrieved 2026-09-26T04:48:24.548Z